| Literature DB >> 30746372 |
Daniel Vasile Balaban1, Alina Dima2, Ciprian Jurcut3, Alina Popp4, Mariana Jinga1.
Abstract
BACKGROUND: Celiac crisis (CC), a potentially life-threatening condition, is one of the rare clinical presentations of celiac disease (CD). Several cases have been documented in the literature, mostly in children. AIM: To perform a review of CC cases reported in adult CD patients.Entities:
Keywords: Celiac crisis; Celiac disease; Diarrhea; Malabsorption; Malnutrition
Year: 2019 PMID: 30746372 PMCID: PMC6369385 DOI: 10.12998/wjcc.v7.i3.311
Source DB: PubMed Journal: World J Clin Cases ISSN: 2307-8960 Impact factor: 1.337
Figure 1Flowchart of the articles considered for the final analysis.
Celiac disease published cases – clinical characteristics
| [ | 1 | 43 | F | 20 kg/12 mo | 14.7 | 3 yr | Yes, non-compliance | Yes |
| [ | 1 | 28 | F | - | 14.0 | 21 yr | Yes, non-compliance | - |
| [ | 1 | 26 | F | - | - | 0 | No | Yes |
| [ | 1 | 24 | F | 4-5 kg/1 wk | 17.5 | 0 | No | Yes |
| [ | 1 | 69 | M | No | - | 0 | No | Yes |
| [ | 1 | 46 | F | - | - | 0 | No | Yes |
| [ | 1 | 31 | F | 14 kg/1 mo | 17 | 0 | No | Yes |
| [ | 1 | 43 | M | 35 kg/6 mo | 11 | 0 | No | Yes |
| [ | 2 | 82, 75 | F, M | -, - | -, - | 0, 0 | No, No | Yes, Yes |
| [ | 1 | 64 | F | 10 kg | - | 0 | No | Yes |
| [ | 1 | 52 | F | Yes | - | 0 | No | - |
| [ | 1 | 30 | F | 9 kg/1 mo | 21.5 | 0 | No | Yes |
| [ | 1 | 83 | M | - | - | 0 | No | Yes |
| [ | 1 | 67 | M | 18 kg/6 mo | - | 0 | No | Yes |
| [ | 12 | mean 58.9 (34-74) | 8F/4M | 12/12 (5-15 kg) | - | 11/12 – 0 | 11/12 – No; 1/12 - Yes, non-compliance | 12/12 – Yes; corticosteroids 6/12 |
| [ | 1 | 26 | F | - | - | 0 | No | Yes |
| [ | 1 | 50 | F | - | - | 0 | No | Yes |
| [ | 1 | 23 | F | - | 0 | No | Yes | |
| [ | 1 | 58 | M | 20 kg/2 mo | - | 0 | No | Yes |
| [ | 1 | 49 | F | 35 kg/3 mo | - | - | No | Yes |
| [ | 1 | 56 | F | 15 kg | - | 2 yr | Yes, non-compliance | Yes, corticosteroids |
| [ | 1 | 38 | M | Yes | - | 0 | No | Yes |
| [ | 1 | 50 | M | 13 kg/2 mo | - | 0 | No | Yes |
| [ | 1 | 37 | F | Yes | - | 0 | No | Yes |
| [ | 1 | 26 | F | - | 19.9 | 2 yr | Yes, non-compliance | Yes, prednisone |
| [ | 1 | 30 | F | 15 kg/3 yr | - | 0 | No | Yes |
| [ | 2 | 75, 55 | M, F | Yes, - | 14.7, - | 0, 0 | No, No | Yes |
| [ | 1 | 36 | F | 4 kg/9 d | 16.3 | 0 | No | Yes |
| [ | 1 | 58 | M | 15 kg | 17.3 | 0 | No | Yes |
BMI: Body mass index; CD: Celiac disease; GFD: Gluten-free diet.
Celiac disease published cases – paraclinical characteristics
| [ | 1 | Yes, Marsh 3c | - | P, 608 U | - | Hb – L (7.8 g/dL), PLT – L | INR – H (2.1), aPTT – H (45 s) |
| [ | 1 | Yes | P | P | P | - | - |
| [ | 1 | Yes | - | P (> 100 U) | - | Hb – H (15.8 g/dL) | - |
| [ | 1 | Yes, Marsh 3c | - | P (99 U/mL) | - | Hb – L (9.3 g/dL) | INR – H (3.2) |
| [ | 1 | Yes | - | P (132 U) | - | Hb – L (4.8-12.2 g/dL) | INR – H (1.3) |
| [ | 1 | Yes, Marsh 3c | - | P (48 U) | P/(39 U) | Hb – L (11.0 g/dL) | - |
| [ | 1 | Yes | - | - | - | - | INR – H (3.5) |
| [ | 1 | Yes, Marsh 4 | - | P (19 UI/mL) | - | - | - |
| [ | 2 | Yes | P (3+) | P (200 RU/mL) | - | Hb – L (8.1 g/dL), PLT – L (180000/dL) | - |
| Yes | P (+1) | P (200 RU/mL) | Hb – L (7.6 g/dL), PLT – L (156000/dL) | - | |||
| [ | 1 | Yes, Marsh 4 | P | P (> 200 U/mL) | P | Hb – L (8.7 g/dL) | - |
| [ | 1 | Yes | - | - | - | Hb – L | - |
| [ | 1 | Yes | P (> 1/1280) | - | - | Hb – NR (12.3 g/dL) | - |
| [ | 1 | Yes | P | N | - | - | - |
| [ | 1 | Yes, Marsh 3 | N | N | N | Hb – NR (12.4 g/dL), PLT – L (160000/dL) | - |
| [ | 12 | Yes 12/12, ≥ Marsh 3a | - | P, 10/11 | - | - | - |
| [ | 1 | Yes, Marsh 3 | P (92 U/mL) | - | P/(20 U/mL) | - | - |
| [ | 1 | Yes | P (1:160) | P (15 EU/mL) | - | - | - |
| [ | 1 | Yes, Marsh 3b | - | P (33.9 U/L) | P/(41.9 U/L) | Hb – NR, PLT – L (94000/dL) | - |
| [ | 1 | Yes, Marsh 4 | - | P (> 200 U/mL) | - | Hb – L (4.7 g/dL) | - |
| [ | 1 | Yes, Marsh 3c | P | P | - | Hb – L (7.2 g/dL), PLT – L (257000/dL) | INR – H (> 1.5), aPTT – H (154 s) |
| [ | 1 | Yes, Marsh 4 | N | N | - | - | - |
| [ | 1 | Yes, Marsh 3c | P (35.9 U) | P (20.6 U) | - | Hb – NR (15.2 g/dL) | INR – H (1.6) |
| [ | 1 | Yes, Marsh 3 | P (158.7) | P (> 200 U/mL) | - | Hb - L (9.4 g/dL) | - |
| [ | 1 | Yes, Marsh 3 | P | P | AGA P | Hb - L (8 g/dL) | - |
| [ | 1 | Yes, Marsh 3c | - | P (23.4, positive > 12) | AGA P (27.4) | HT - L (18%) | PT < 10% |
| [ | 1 | Yes, Marsh 3b | - | - | AGA P (IgA 63.4, IgG 111.1) | Hb - L | - |
| [ | 2 | Yes, Marsh 3a; Yes, Marsh 3b | P; P | - | AGA N; AGA P | Hb - L (5.9 /dL); Hb - L (7.9 /dL) | PT prolonged (19 s); PT prolonged (18 s) |
| [ | 1 | Yes, Marsh 3c | - | - | - | Hb - L | - |
| [ | 1 | Yes, Marsh 3c | P (1:640) | P (142) | AGA P | Hb - L (11.6 g/dL) | INR – H (1.6) |
L: Low; H: High; N: Normal; M: Masculine; Hb: Hemoglobin; P: Positive, N: Negative: NR: Normal ranges, HT: Hematocrit; AGA: Anti-gliadin antibodies; aPPT: Activated partial thromboplastin time; CD: Celiac disease; DGP: Anti-deamidated gliadin antibodies; EMA: Anti-endomysial antibodies; INR: International normalized ratio; PLT: Platelets; PT: Prothrombin time; tTG: Anti-tissue transglutaminase antibodies.